USE OF (1R,5S)-(+)-1-(NAPHTHALEN-2-YL)-3-AZABICYCLO{3.1.0}HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS

The present invention relates to (lR,5S)-(+)-l-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane and pharmaceutical compositions thereof, and methods employing their use in the treatment of conditions affected by monoamine neurotransmitters, including ADHD and substance abuse.

Saved in:
Bibliographic Details
Main Authors McKinney, Anthony Alexander, Bymaster, Frank
Format Patent
LanguageCroatian
English
Published 04.09.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to (lR,5S)-(+)-l-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane and pharmaceutical compositions thereof, and methods employing their use in the treatment of conditions affected by monoamine neurotransmitters, including ADHD and substance abuse.
Bibliography:Application Number: HR2020P000424T